Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial
| Autor: | Tomasz M. Beer, Bertrand Tombal, Nancy Devlin, Mark Balk, S. Holmstrom, S Naidoo, Teresa Parli, Yohann Loriot, Cristina Ivanescu, De Phung, Marco Pavesi, Michael Herdman |
|---|---|
| Přispěvatelé: | UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Oncology Quality of life medicine.medical_specialty Visual analogue scale Pain Eq-5D Anxiety lcsh:Computer applications to medicine. Medical informatics Placebo 03 medical and health sciences Prostate cancer chemistry.chemical_compound 0302 clinical medicine EQ-5D Surveys and Questionnaires Internal medicine Nitriles Phenylthiohydantoin Post-hoc analysis medicine Enzalutamide Humans 030212 general & internal medicine Aged business.industry Research Public Health Environmental and Occupational Health General Medicine Middle Aged medicine.disease Metastatic castration-resistant prostate cancer Self Care Prostatic Neoplasms Castration-Resistant chemistry 030220 oncology & carcinogenesis Benzamides lcsh:R858-859.7 medicine.symptom business |
| Zdroj: | Health and Quality of Life Outcomes, Vol. 15, no. 1, p. 130-138 (2017) Health and Quality of Life Outcomes Health and Quality of Life Outcomes, Vol 15, Iss 1, Pp 1-9 (2017) |
| Popis: | Background The effect of enzalutamide on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer was analyzed using the generic EQ-5D instrument. Methods Patients received oral enzalutamide 160 mg/day (n = 872) or placebo (n = 845). EQ-5D index and EQ-5D visual analogue scale (EQ-5D VAS) scores were evaluated at baseline, week 13, and every 12 weeks until week 61 due to sample size reduction thereafter. Changes on individual dimensions were assessed, and Paretian Classification of Health Change (PCHC) and time-to-event analyses were conducted. Results With enzalutamide, EQ-5D index and EQ-5D VAS scores declined more slowly versus placebo and time to diverge from full health was prolonged. Average decline in EQ-5D index (−0.042 vs. –0.070; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|